Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis

Hughes, D.; Bokobza, Idan; Carr, S.B.

doi:10.1183/13993003.03636-2020

Cited by 9 publications

(7 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Pulmonary mycobacteriosis is severe in individuals with a predisposition to infection and in individuals with comorbidities in the United States [ 22 ], South Korea [ 23 , 24 ], and China [ 25 ]. In particular, patients with cystic fibrosis are predisposed to colonization and NTM infection [ 26 , 27 ].…”

Section: Incidence Of Mycobacterioses In Humans In the Last Three Yearsmentioning

confidence: 99%

Nontuberculous Mycobacteria: Ecology and Impact on Animal and Human Health

2022

View full text Add to dashboard Cite

Nontuberculous mycobacteria (NTM) represent an important group of environmentally saprophytic and potentially pathogenic bacteria that can cause serious mycobacterioses in humans and animals. The sources of infections often remain undetected except for soil- or water-borne, water-washed, water-based, or water-related infections caused by groups of the Mycobacterium (M.) avium complex; M. fortuitum; and other NTM species, including M. marinum infection, known as fish tank granuloma, and M. ulcerans infection, which is described as a Buruli ulcer. NTM could be considered as water-borne, air-borne, and soil-borne pathogens (sapronoses). A lot of clinically relevant NTM species could be considered due to the enormity of published data on permanent, periodic, transient, and incidental sapronoses. Interest is currently increasing in mycobacterioses diagnosed in humans and husbandry animals (esp. pigs) caused by NTM species present in peat bogs, potting soil, garden peat, bat and bird guano, and other matrices used as garden fertilizers. NTM are present in dust particles and in water aerosols, which represent certain factors during aerogenous infection in immunosuppressed host organisms during hospitalization, speleotherapy, and leisure activities. For this Special Issue, a collection of articles providing a current view of the research on NTM—including the clinical relevance, therapy, prevention of mycobacterioses, epidemiology, and ecology—are addressed.

show abstract

Section: Incidence Of Mycobacterioses In Humans In the Last Three Yearsmentioning

confidence: 99%

Nontuberculous Mycobacteria: Ecology and Impact on Animal and Human Health

2022

View full text Add to dashboard Cite

show abstract

“…Eradication of M. abscessus can be achieved in 48 to 65% of children 95 96 and less often in adults. Treatment regimens for M. abscessus are not evidence-based and involve complex and often poorly tolerated drug combinations for prolonged periods (>12 months).…”

Section: Recommendations For the Management Of Other Cystic Fibrosis ...mentioning

confidence: 99%

Antimicrobial Strategies for Cystic Fibrosis

Møller

Pressler

Qvist

2022

Semin Respir Crit Care Med

View full text Add to dashboard Cite

Lung infection is the leading cause of death in cystic fibrosis (CF), and antimicrobial therapies are the backbone of infection management. While many different strategies may be applied, rigorous microbiological surveillance, intensive eradication therapy, and long-term maintenance therapy based on inhaled antibiotics may be considered the main strategy for infection control in individuals with CF. While most of the existing evidence is based on infection with Pseudomonas aeruginosa, other important pathogens causing lung inflammation and deterioration exist and should be treated despite the evidence gap. In this chapter, we describe the approaches to the antimicrobial treatment of the most important pathogens in CF and the evidence behind.

show abstract

“…Treatment outcome data are very limited. In a retrospective review of pwCF from Colorado, the rate of eradication for MAC was 60% [38] and 67% among children with CF in London [39 ▪ ]. Treatment of pulmonary disease due to M. abscessus is complicated because of significant levels of in vitro resistance, the need for intravenous antibiotics, common adverse reactions, and generally poor outcomes.…”

Section: Treatment Of Nontuberculous Mycobacteria Pulmonary Disease A...mentioning

confidence: 99%

Nontuberculous mycobacteria in cystic fibrosis

Nick

Daley

Lenhart-Pendergrass

et al. 2021

Current Opinion in Pulmonary Medicine

View full text Add to dashboard Cite

Purpose of reviewNontuberculous mycobacteria (NTM) are challenging infections among people with cystic fibrosis (pwCF) as the source, modes of transmission, and best practices for diagnosis and treatment are not known. Investigators have defined aspects of NTM infection that are unique to the CF population, as well as features shared with other conditions at risk. This review describes recent advances in our understanding of NTM infection among pwCF.Recent findingsThe presence of dominant circulating clones of Mycobacterium abscessus within the CF community worldwide continue to be described, as well as pathogen phenotypes that could evoke greater environmental fitness and infectivity. The risk of direct or indirect transmission between pwCF remains an active focus of investigation, with divergent findings and conclusions reached in a site-specific fashion. Derived largely from studies in non-CF populations, new clinical guidelines are now available. A wide variety of agents are in preclinical development or early phase trials with promising findings, and new therapeutic targets have been identified as our understanding of the complex biology of NTM continues to expand.SummarySignificant challenges remain in the fight against NTM, however, recent advances in our understanding of the genetics, epidemiology and pathophysiology of pulmonary NTM infection in pwCF are leading efforts to improve clinical care.

show abstract

Eradication success for non-tuberculous mycobacteria in children with cystic fibrosis

Cited by 9 publications

References 17 publications

Nontuberculous Mycobacteria: Ecology and Impact on Animal and Human Health

Nontuberculous Mycobacteria: Ecology and Impact on Animal and Human Health

Antimicrobial Strategies for Cystic Fibrosis

Nontuberculous mycobacteria in cystic fibrosis

Contact Info

Product

Resources

About